Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02937558
Other study ID # XSGO-CH01
Secondary ID 1R44DK105691-01
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2016
Est. completion date October 2018

Study information

Verified date November 2019
Source Xeris Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose infusion rates in children < 1 year of age with congenital hyperinsulinism.


Description:

This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind (DB) parallel group study with open-label follow-up designed to evaluate the efficacy of CSI-Glucagon™ for the prevention of hypoglycemia with lower IV glucose infusion rates when delivered subcutaneously to patients up to 1 year of age with congenital hyperinsulinism. CSI-Glucagon™ is expected to provide a better inpatient treatment option compared to the current standard of care.

The study will consist of three phases:

1. Baseline Phase: First is a baseline stabilization phase during which concomitant therapy with octreotide and diazoxide will be safely weaned and continuous enteric feed will be held constant to the degree possible, with the only factors varying being meal size and IV glucose infusion rate (GIR) adjusted by a set plasma glucose measurement driven algorithm.

2. Blinded, Randomized Treatment Phase: Following the stabilization phase, subjects will be randomly assigned to blinded treatment with either glucagon or placebo, which will be delivered for up to 48 hours with an OmniPod® infusion pump with the controller set to a starting basal rate for glucagon of 5 μg/kg/hr and GIR adjustments used to maintain euglycemia. After 48 hours of blinded treatment, all subjects will transition to open-label active treatment. However, if GIR reduction from baseline is < 20% at 24 hours, subjects will be transitioned early to the open-label phase.

3. Open-label Treatment Phase: The third study period will involve use of CSI-Glucagon™ to manage blood glucose with minimal GIR for up to 28 days of cumulative exposure.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date October 2018
Est. primary completion date September 2018
Accepts healthy volunteers No
Gender All
Age group N/A to 12 Months
Eligibility Inclusion Criteria:

1. Diagnosed with hyperinsulinism:

a. Biochemical; detectable insulin (i.e., =1 µIU/L) at time of hypoglycemia (i.e, blood glucose <50 mg/dl), and/or suppressed free fatty acids (FFA), and/or suppressed beta-hydroxybutyrate (BOHB) and/or glycemic response to glucagon at time of hypoglycemia.

2. Absolute necessity of intravenous glucose to prevent hypoglycemia:

1. Having failed diazoxide therapy as defined by inadequacy of 5 days maximum dose of diazoxide to eliminate the need for IV glucose, not necessarily that diazoxide has no effect.

2. May be on diazoxide and/or octreotide, but these drugs will be weaned off prior to randomization.

3. May be on dextrose feeds.

3. Patient may be a participant in other study protocols such as observational studies, as long as no investigational intervention has taken place within 24 hrs. prior to screening.

4. Less than 12 months of age at screening.

Exclusion Criteria:

1. History of allergy to glucagon or excipients in the CSI-Glucagon formulation.

2. Currently receiving, or less than 12 hours removed from IV glucagon treatment that resulted in a best achievable GIR > 8 mg/(kg*min), prior to the start of study drug.

3. Diazoxide naïve or within five days of starting diazoxide.

4. Receiving steroids at doses larger than 20 mg/m2/day (hydrocortisone equivalent).

5. Patients with sepsis.

6. Receiving alpha or beta agonists for blood pressure support.

7. Received an investigational or other study drug within 5 half-lives of drug.

8. Body weight less than or equal to 2.3 kg/5.0 lbs.

9. History of pancreatectomy and GIR < 8 mg/(kg*min) after weaning of all concomitant therapies.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Glucagon
Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
Other:
Placebo
Isotonic saline

Locations

Country Name City State
United States Cook Children's Medical Center Fort Worth Texas
United States Baylor College of Medicine, Texas Children's Hospital Houston Texas
United States UCLA Mattel Children's Hospital Los Angeles California
United States Washington University, St. Louis Children's Hospital Saint Louis Missouri
United States UCSF School of Medicine, Division of Pediatric Endocrinology San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
Xeris Pharmaceuticals National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind) Change from baseline in glucose infusion rate (GIR) will be determined for each subject at 24 and 48 hours from the start of blinded treatment. Subjects with a decrease in GIR = 20% at 24 hours, and = 33% at 48 hours will be considered to have had a clinically meaningful treatment response. Baseline to end of blinded treatment at 24 or 48 hours
Secondary Percent Change in GIR (Double-Blind) The groups will be compared for mean percent change in GIR from baseline to the end of the double-blind study phase. Baseline to the end of blinded treatment at 24 or 48 hours
Secondary Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Open-Label) Change from baseline in glucose infusion rate (GIR) will be determined for each subject at the end of open-label treatment. Subjects with a decrease in GIR = 33% will be considered to have had a clinically meaningful treatment response. Baseline to the end of open-label treatment at 72 hours
Secondary Percent Change in Glucose Infusion Rate (Open-Label) The groups will be compared for mean percent change in GIR from baseline to the end of the open-label study phase. Baseline to end of treatment at 72 hours
See also
  Status Clinical Trial Phase
Recruiting NCT02021604 - Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma Phase 1
Recruiting NCT04732416 - HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) Phase 2
Completed NCT02604485 - A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism Phase 2
Recruiting NCT04205604 - 18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism Phase 2
Completed NCT00897676 - Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity Phase 1/Phase 2
Completed NCT00987168 - Sandostatine® LP and Hyperinsulinism Phase 2
Active, not recruiting NCT03941236 - Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism Phase 3
Completed NCT03042416 - 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Phase 3
Completed NCT04172441 - Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism Phase 2/Phase 3
Recruiting NCT04706910 - 18F-DOPA II - PET Imaging Optimization Phase 3
Recruiting NCT06208215 - RZ358 Treatment for Congenital Hyperinsulinism Phase 3
Completed NCT03777176 - A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism Phase 3
Recruiting NCT03768518 - GLP-1 Receptor Expression in CHI
Completed NCT04538989 - An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism Phase 2
Completed NCT01070758 - Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy Phase 4
Completed NCT00674440 - Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism Phase 2
Terminated NCT00835328 - Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia Phase 1/Phase 2
Completed NCT00571324 - Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism Phase 1/Phase 2
Withdrawn NCT03053284 - Pasireotide in Hyperinsulinemic Hypoglycemia Phase 2
No longer available NCT02835131 - Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia